+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Treatment of Hodgkins disease in children with VAMP and VEPA

Treatment of Hodgkins disease in children with VAMP and VEPA

Pediatric Hematology & Oncology 16(2): 141-148, March-April

Treatment of Hodgkin's disease in children should be directed at maximizing cures and minimizing the long-term effects of alkylating agents, anthracyclines, and bleomycin. In this study methotrexate and etaposide were used in the VAMP/VEPA regimens to treat 60 clinically staged pediatric patients with Hodgkin's disease. Twenty-nine patients with stages I-IIA received four courses of VAMP plus low-dose radiotherapy. Thirty-one IIA bulky disease and IIB-IVB patients received four or six courses of VEPA plus low-dose radiotherapy. There were 6 partial remissions after the completion of chemotherapy and all of these patients relapsed, but 4 were successfuly salvaged with ABMT. Two patients have died. The 3.1-year overall survival rate is 97% (100% VAMP, 94% VEPA) and the event-free survival rate is 88% (97% VAMP, 77% VEPA). These results suggest that VAMP is a reasonable treatment for low stages of Hodgkin's disease, but more advanced disease is not adequately treated by VEPA and low-dose radiotherapy.

(PDF emailed within 1 workday: $29.90)

Accession: 035980500

Download citation: RISBibTeXText

Related references

Treatment of Hodgkin's disease in children with VAMP (vinblastine, adriamycin, methotrexate, prednisone) and VEPA (vinblastine, etoposide, prednisone, adriamycin). Pediatric Hematology and Oncology 16(2): 141-148, 1999

Major prognostic factors of adult patients with advanced B-cell lymphoma treated with vincristine, cyclophosphamide, prednisone and doxorubicin (VEPA) or VEPA plus methotrexate (VEPA-M). Japanese Journal of Clinical Oncology 18(2): 113-124, 1988

Vesicle associated membrane protein (VAMP)-7 and VAMP-8, but not VAMP-2 or VAMP-3, are required for activation-induced degranulation of mature human mast cells. European Journal of Immunology 38(3): 855-863, 2008

VAMP chemotherapy and low dose involved field irradiation for early stage Hodgkins disease. Pediatric Research 47(4 Part 2): 254A, April, 2000

Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin's lymphoma treated with VEPA or VEPA-M. Journal of Clinical Oncology 6(1): 128-141, 1988

VAMP-1, VAMP-2 and VAMP-3/cellubrein expression in cells of the B lineage A role in constitutive vesicle trafficking. Molecular Biology of the Cell 9(SUPPL ): 207A, 1998

Induction treatment with VAMP/C-VAMP infusional chemotherapy in previously untreated myeloma. Blood 86(10 SUPPL 1): 186A, 1995

Salvage treatment with VAMP/C-VAMP infusional chemotherapy and high dose melphalan in refractory myelomas. British Journal of Haematology 93(SUPPL 2): 87, 1996

Treatment of unfavorable childhood Hodgkin's disease with VEPA and low-dose, involved-field radiation. Journal of Clinical Oncology 20(14): 3088-3094, 2002

Treatment of hodgkins disease in children. 1986

Role of VAMP-2, VAMP-7, and VAMP-8 in constitutive exocytosis from HSY cells. Histochemistry and Cell Biology 125(3): 273-281, 2005

A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma. British Journal of Haematology 97(1): 153-160, 1997

Outcome of Hodgkins Disease patients diagnosed and treated for Tuberculosis during there treatment for Hodgkins Disease. Blood 102(11): 293b, November 16, 2003

Late effect of hodgkins disease treatment in children. Kamps, W A , G B Humphrey And S Poppema Cancer Treatment And Research: Hodgkin's Disease in Children: Controversies And Current Practice Xvii+334p Kluwer Academic Publishers: Dordrecht, Netherlands; Boston, Massachusetts, Usa Illus 195-220, 1989